Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 10/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782686 | 0.89 | DNM1 (0.43) | HTTDNM1KMT2ACNR1CNR2 | |
| SCHEMBL19630714 | 0.83 | DNM1 (0.40) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL7534332 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH | |
| SCHEMBL7540762 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH | |
| SCHEMBL7540736 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH | |
| SCHEMBL817870 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH | |
| SCHEMBL7535052 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH | |
| SCHEMBL7533182 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH | |
| SCHEMBL3261321 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH | |
| SCHEMBL7539638 | 0.82 | TSHR (0.55) | CNR1CNR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1014999-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1999015186-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | claimed |
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6692732-B2 | Administering cationic polymers to mammals to prevent poisons or antigens from microorganisms such as bacteria, viruses, fungi or parasites; deactivation | GENZYME CORPORATION | 2004-02-17 | — | — | US | disclosed |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-6482402-B1 | BACTERICIDE AND CATIONIC POLYMER | GELTEX PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1014999-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6007803-A | ADMINISTERING TO MAMMAL A CATIONIC POLYMER TO INHIBIT PATHOGENIC TOXINS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999015186-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | PIGS, ANTXR2, MSN | HTT 166/4885DNM1 424/4885KMT2A 3812/4885 |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | PIGS, ANTXR2, MSN | HTT 166/4885DNM1 424/4885KMT2A 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.